Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
12°
Light Snow
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellipharmaceutics
(TSX:
IPCI
)
N/A
UNCHANGED
Last Price
Updated: 10:01 AM EST, Mar 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
0.0700 (10)
Ask (Size)
0.1200 (20)
Prev. Close
0.0800
Today's Range
N/A - N/A
52wk Range
0.0600 - 0.1250
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
March 13, 2024
Via
ACCESSWIRE
Intellipharmaceutics Announces Cease Trade Order
March 06, 2024
Via
ACCESSWIRE
Performance
More News
Read More
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
February 26, 2024
Via
ACCESSWIRE
Intellipharmaceutics International Inc. Announces Stock Option Grant
February 08, 2024
Via
ACCESSWIRE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
January 02, 2024
Via
ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2023 Results
October 16, 2023
Via
ACCESSWIRE
Intellipharmaceutics Reports Director Election Results
September 14, 2023
Via
ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2023 Results
July 14, 2023
Via
ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2022 Results
October 14, 2022
Via
ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
August 16, 2022
Via
ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2022 Results
July 21, 2022
Via
ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2022 Results
July 21, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
July 15, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Exposures
COVID-19
Intellipharmaceutics Reports Director Election Results
May 27, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Announces First Quarter 2022 Results
April 14, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Announces Fiscal Year 2021 Results
February 28, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Reports Director Election Results
February 04, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
January 13, 2022
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Comments on Recent Trading Activity
December 22, 2021
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Announces Third Quarter 2021 Results
October 15, 2021
From
Intellipharmaceutics International Inc.
Via
AccessWire
Topics
Bankruptcy
Intellectual Property
Exposures
COVID-19
Financial
Intellectual Property
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
April 22, 2021
From
Intellipharmaceutics International Inc.
Via
AccessWire
Intellipharmaceutics Announces First Quarter 2021 Results
April 14, 2021
From
Intellipharmaceutics International Inc.
Via
AccessWire
Topics
Bankruptcy
Intellectual Property
Exposures
COVID-19
Financial
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
